MXPA05003616A - Composiciones que comprenden anfotericina b altamente purificada. - Google Patents

Composiciones que comprenden anfotericina b altamente purificada.

Info

Publication number
MXPA05003616A
MXPA05003616A MXPA05003616A MXPA05003616A MXPA05003616A MX PA05003616 A MXPA05003616 A MX PA05003616A MX PA05003616 A MXPA05003616 A MX PA05003616A MX PA05003616 A MXPA05003616 A MX PA05003616A MX PA05003616 A MXPA05003616 A MX PA05003616A
Authority
MX
Mexico
Prior art keywords
compositions
amphotericin
highly purified
purified amphotericin
mammal
Prior art date
Application number
MXPA05003616A
Other languages
English (en)
Inventor
Robert Kramer
Original Assignee
Univ Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mississippi filed Critical Univ Mississippi
Publication of MXPA05003616A publication Critical patent/MXPA05003616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un metodo para tratar infecciones por hongo en un mamifero que comprende administrar una cantidad terapeuticamente efectiva de una composicion que comprende anfotericina B, y un portador farmaceuticamente aceptable, en donde la anfotericina B es substancialmente pura.
MXPA05003616A 2002-10-03 2003-10-03 Composiciones que comprenden anfotericina b altamente purificada. MXPA05003616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41567102P 2002-10-03 2002-10-03
PCT/US2003/031390 WO2004030677A1 (en) 2002-10-03 2003-10-03 Compositions comprising highly purified amphotericin b

Publications (1)

Publication Number Publication Date
MXPA05003616A true MXPA05003616A (es) 2006-01-24

Family

ID=32069895

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003616A MXPA05003616A (es) 2002-10-03 2003-10-03 Composiciones que comprenden anfotericina b altamente purificada.

Country Status (9)

Country Link
US (1) US7867981B2 (es)
EP (1) EP1551423B1 (es)
JP (1) JP5170940B2 (es)
AT (1) ATE391508T1 (es)
AU (1) AU2003279776B2 (es)
CA (1) CA2500716A1 (es)
DE (1) DE60320283T2 (es)
MX (1) MXPA05003616A (es)
WO (1) WO2004030677A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128728A1 (en) * 2005-12-28 2012-05-24 Novartis Pharma Ag Compositions Comprising Amphotericin B
US20100210575A1 (en) * 2007-06-29 2010-08-19 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
DK2344198T3 (da) * 2008-09-27 2020-11-30 Jina Pharmaceuticals Inc Lipidbaserede farmaceutiske præparater til topisk anvendelse
CA2906765A1 (en) 2013-03-15 2014-09-18 Biochemics, Inc. Topical formulations and methods for drug delivery
DE102015102210A1 (de) * 2015-02-16 2016-08-18 Heraeus Medical Gmbh Antimykotischer polymerisierbarer Knochenzement und ein Verfahren zu seiner Herstellung
EP3624770A1 (en) 2017-05-15 2020-03-25 BioChemics, Inc. Transdermally-delivered combination drug therapy for pain
CN114605484A (zh) * 2020-12-09 2022-06-10 上海上药新亚药业有限公司 一种获得两性霉素b新晶型的纯化方法
CN112666284A (zh) * 2020-12-11 2021-04-16 南京明捷生物医药检测有限公司 一种测定蛋白溶液中两性霉素b含量的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH556879A (de) * 1971-04-23 1974-12-13 Le Nii Antibiotikov Verfahren zur gewinnung und chemischen reinigung von amphoterizin b.
US4035568A (en) 1971-06-07 1977-07-12 Rutgers Research And Educational Foundation Derivatives of polyene macrolide antibiotics
US3965090A (en) 1973-03-05 1976-06-22 E. R. Squibb & Sons, Inc. Amphotericin complexes
US4049898A (en) 1973-03-05 1977-09-20 E. R. Squibb & Sons, Inc. Amphotericin complexes containing oxalic acid and calcium
US4054734A (en) 1975-03-03 1977-10-18 E. R. Squibb & Sons, Inc. Amphotericin complexes containing citric acid and calcium
US4308375A (en) * 1980-10-06 1981-12-29 E. R. Squibb & Sons, Inc. Method for purifying water-insoluble polyene antibiotics
US4656288A (en) * 1984-03-29 1987-04-07 Takeda Chemical Industries, Ltd. Antibiotics, their production and use
US4663167A (en) 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4766046A (en) 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
JP2705175B2 (ja) * 1987-03-05 1998-01-26 ザ リポソーム カンパニー，インコーポレイテッド 低毒性薬剤‐脂質系
US4902789A (en) * 1987-10-27 1990-02-20 E. R. Squibb & Sons, Inc. Process and composition for the purification of amphotericin B
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
DE69130832T2 (de) * 1990-11-16 1999-10-07 Nippon Shinyaku Co Ltd Injizierbare amphotericin b enthaltende dispersion
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6211140B1 (en) * 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
US7531693B2 (en) * 2003-05-22 2009-05-12 Molecular Transfer, Inc. Lipids for transfection of nucleic acids

Also Published As

Publication number Publication date
US20060105968A1 (en) 2006-05-18
EP1551423A1 (en) 2005-07-13
JP2006504716A (ja) 2006-02-09
AU2003279776A1 (en) 2004-04-23
AU2003279776B2 (en) 2009-09-24
US7867981B2 (en) 2011-01-11
CA2500716A1 (en) 2004-04-15
WO2004030677A1 (en) 2004-04-15
EP1551423B1 (en) 2008-04-09
DE60320283T2 (de) 2009-08-27
ATE391508T1 (de) 2008-04-15
JP5170940B2 (ja) 2013-03-27
DE60320283D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
WO2001054679A3 (en) Transdermal composition containing an anesthetic and a vasodilator agent
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
GB0101577D0 (en) Compounds
MY135683A (en) Compositions for improving fertility
WO2002042295A3 (en) Peptides as met-ap2 inhibitors
IL159724A0 (en) A nitrogen oxide generating composition for treatment of nail infections
GB9917406D0 (en) Compounds
PT1458360E (pt) Derivados de indole como agonistas do recetor s1p1
HK1040636A1 (en) Therapeutic agent for the suppression of snoring noises
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
HK1125291A1 (en) Method of using guava extract and composition including guava extract
WO2004052308A3 (en) Topical anti-infective formulations
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
MXPA05003616A (es) Composiciones que comprenden anfotericina b altamente purificada.
MXPA01011606A (es) Terapia anti-inflamatoria para infeccion mediada por inflamacion.
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
IL143985A0 (en) New use of melagatran
SE0004101D0 (sv) New use
WO2001030379A3 (en) Compositions and methods for preventing and treating transplant rejection
MXPA04002389A (es) Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
NO20035038D0 (no) Forhindring av avhengighet ved smertebehandling
ATE439126T1 (de) Antitumorale terpen-verbindungen
DK1181300T3 (da) 6-O-carbamatketolidderivater

Legal Events

Date Code Title Description
FG Grant or registration